trending Market Intelligence /marketintelligence/en/news-insights/trending/_h0NrZI1IxmKvqX6eRURTQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merrimack Pharmaceuticals settles lawsuit related to asset sale to Ipsen

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Merrimack Pharmaceuticals settles lawsuit related to asset sale to Ipsen

Merrimack Pharmaceuticals Inc. agreed to resolve a lawsuit, pending in the Court of Chancery in the State of Delaware, filed against the company by certain holders of its convertible notes.

The noteholders, Wolverine Flagship Fund Trading Ltd., 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund LP, and Wells Fargo Bank NA, alleged the company was obligated to offer to repurchase its outstanding 4.50% convertible notes due 2020 in connection with its asset sale to Ipsen SA.

Under the settlement, the company will pay about $32.5 million in cash to the plaintiffs, representing 90 cents per $1 of convertible notes, plus accrued unpaid interest on the notes. Merrimack will also pay a total of about $3.8 million for the plaintiffs' attorneys' fees and expenses.

The noteholders collectively hold about $35.8 million aggregate principal amount of the notes.

Merrimack also agreed to start a tender offer for all remaining convertible notes at 90 cents per $1 of convertible notes, plus accrued interest, which would eliminate all of its remaining debt if all noteholders participate.